MedTrace Logo

A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension

NCT00465803 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2014-07-24

No results posted yet for this study

Summary

The purpose of this study is to assess patient compliance with DuoTrav versus concomitant administration of Timolol 0.5% plus TRAVATAN in patients with open-angle glaucoma or ocular hypertension.

Conditions

Interventions

DRUG

Travoprost 0.004%/timolol 0.5% ophthalmic solution

One drop in the study eye(s) once daily at either 8 AM or 8 PM for twelve months using the Dosing Aid

DRUG

Travoprost ophthalmic solution, 0.004%

One drop in the study eye(s) once daily at 8 PM for twelve months using the Dosing Aid

DRUG

Timolol maleate ophthalmic solution, 0.5%

One drop in the study eye(s) once daily at 8 AM or twelve months using the Dosing Aid

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Theresa Landry · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00465803 on ClinicalTrials.gov